Skip to main content

Advertisement

Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

Fig. 1

Changes of tumor lesions in sequential PET-CT examinations in the period of CART-EGFR cell infusion. a PET-CT examination illustrated hepatic hilar malignancy before surgery. b PET-CT examined after the completion of radiotherapy with illustration of a new metastatic hypermetabolic lesion in the hepatic caudate lobe and enlarged soft tissue and retroperitoneal lymph node metastases. c PET-CT assessment 6 weeks after the infusion of CART-EGFR cells showed a more than 80% shrinkage of metastatic lesions in the hepatic hilar region and caudate lobe. d Routine examination by PET-CT showed a persistent PR status 4 months after the CART-EGFR cell infusion. e PET-CT detected multiple new SUV abnormal lesions in the omentum majus, peritoneum, and abdominal cavity 8.5 months after the first cycle of CART-EGFR cell infusion. f The examination of PET-CT detected newly emerged metastases in the bottom of the pelvis, right liver lobe, and left supraclavicular lymph node as well as enlargement of previous tumor lesions in the abdomen 4 weeks after the combination of anti-PD-1 antibody and CART-EGFR

Back to article page